Pfizer’s stock has fallen 45% over five years but stabilized recently, down just 6% since 2025. Despite the dip, the company boasts a stellar 351-quarter dividend streak—with payouts more than double since 2011—and free cash flow comfortably covers those payments. While patent expirations pose risks, Pfizer’s low valuation (under 9x future earnings) offers potential safety for income-focused investors looking beyond pandemic-era volatility.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
